Search

Puma Biotechnology and Pierre Fabre Amend NERLYNX® License Agreement to Include Greater China

Puma Biotechnology and CANbridge Pharmaceuticals Terminate License Agreement in Greater China


"Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, and Pierre Fabre, a leading French pharmaceutical company, have agreed to extend the terms of the 2019 license agreement which grants Pierre Fabre exclusive rights to develop and commercialize NERLYNX® (neratinib) within Europe, Turkey, Middle East and Africa. The amended agreement extends Pierre Fabre’s commercial rights for NERLYNX to Greater China, which includes mainland China, Taiwan, Hong Kong and Macau...."


"Our oncology team based in Shanghai is fully committed to start the commercialization of NERLYNX, which perfectly complements our existing NAVELBINE chemotherapy in breast and lung cancers.”


012721 Puma Biotechnology and Pierre Fab
.
Download • 193KB